That is the big give away, they had to unload the shares to buy ZIOP
Zacks By Zacks Equity Research
1 hour ago
Estimates for SGYP have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #2 (Buy), so the recent move higher for this spotlighted company may definitely continue over the next few weeks
YES ! you program it and it does sleep patterns and heart rate does it all google it. You don't have to have it on you.
Esperion Therapeutics (ESPR) Weakness Overdone Amid FDA AdCom on SNY/REGN's Praluent, UBS UBS analyst Andrew Peters maintained a Buy rating and price target of $140 on Esperion Therapeutics (NASDAQ: ESPR)
CyberArk Files For Secondary Offering After Strong Q1
BY GILLIAN RICH, INVESTOR'S BUSINESS DAILY
6-8-15 08:54 AM ET
CyberArk Software (NASDAQ:CYBR) said Friday it filed for a follow-on stock offering.
The cybersecurity company filed a registration statement with the Securities and Exchange Commission for the secondary offering. The majority of the shares will be sold by current shareholders with $50 million in shares to be sold by CyberArk. The total number of shares to be sold hasn't been decided yet.
Ambarella Earnings Accelerate Further With Drone Growth Seen Adding Boost